In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on BioCardia (BCDA – Research Report), with a price target of $9.00. The company’s shares closed last Monday at $2.62.
Pantginis covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, Panbela Therapeutics, and Tempest Therapeutics. According to TipRanks, Pantginis has an average return of -3.0% and a 37.92% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCardia with a $9.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on BioCardia’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $64 thousand and a GAAP net loss of $3.5 million. In comparison, last year the company had a GAAP net loss of $3.33 million
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Read More on BCDA:
- BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
- BioCardia prices 1.13M shares registered direct offering at $2.336 per share
- BioCardia enters into purchase agreement to sell 1.13M shares at $2.336
- BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
- BioCardia announces CBER completed review of CardiAMP analysis
